Comparing Fractyl Health (NASDAQ:GUTS) and Glaukos (NYSE:GKOS)

Fractyl Health (NASDAQ:GUTS) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Analyst Ratings

This is a breakdown of current ratings for Fractyl Health and Glaukos, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	0	0	1	0	3.00
Glaukos	1	0	11	1	2.92

Fractyl Health currently has a consensus price target of $10.00, indicating a potential upside of 890.10%. Glaukos has a consensus price target of $159.50, indicating a potential upside of 77.13%. Given Fractyl Health’s stronger consensus rating and higher probable upside, equities analysts clearly believe Fractyl Health is more favorable than Glaukos.

Earnings & Valuation

This table compares Fractyl Health and Glaukos”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$93,000.00	531.28	-$77.09 million	($1.53)	-0.66
Glaukos	$383.48 million	13.28	-$134.66 million	($2.87)	-31.38

Fractyl Health has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Fractyl Health has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.

Institutional & Insider Ownership

99.0% of Glaukos shares are owned by institutional investors. 6.4% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Fractyl Health and Glaukos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fractyl Health	-64,849.48%	N/A	-57.21%
Glaukos	-39.04%	-16.53%	-10.61%

Summary

Glaukos beats Fractyl Health on 8 of the 15 factors compared between the two stocks.

About Fractyl Health

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.